(B-F) After 24h in culture with either 250uM melatonin or vehicle control the concentrations of IL-5 (B), IL-13 (C) , IL-9 (D) IL-10 (E) , and IL-6 (F) was determined by LEGENDPlex assay
Careful monitoring is essential, as overuse of IV therapy may cause complications like electrolyte imbalances or vein irritation
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
This period establishes the foundation for future growth
Together, they form one of the most important nutrient pairings for overall health, and one of the most commonly depleted among GLP-1 users
As a guide, dosage should not exceed 2 mg